BPC-157 vs Orforglipron
Extensively Studied vs Extensively Studied
compatible No known interactions; may support gut health and potentially mitigate GI adverse effects.
Molecular Data
BPC-157 Orforglipron
Weight 1,419.53 Da 882.974 Da
Half-life <30 minutes 25-68 hours
Chain 15 amino acids Non-peptide small molecule
Type Pentadecapeptide Small-molecule GLP-1R agonist
Key Benefits
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Orforglipron
01 Significant weight loss (up to 12.4% at 72 weeks)
02 Robust diabetes control (HbA1c reduction 1.3-1.6%)
03 Once-daily oral tablet format
04 No refrigeration or food restrictions required
05 Reduced cardiovascular risk markers
Dosing Protocols
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Orforglipron
Start 3-6mg daily, titrate up to 12-36mg based on response / Once daily oral tablet
Side Effects
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Orforglipron
Diarrhea (more prevalent than with injectable GLP-1s)
Nausea (typically improves after first month)
Appetite reduction
Contraindications
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy and breastfeeding
Research Evidence
BPC-157 Orforglipron
Status Extensively Studied Extensively Studied
References 6 studies 4 studies
Latest January 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.